Literature DB >> 22050724

Transplant accommodation--are the lessons learned from xenotransplantation pertinent for clinical allotransplantation?

A Dorling1.   

Abstract

"Accommodation" refers to a vascularized transplant that has acquired resistance to antibody-mediated rejection (AMR). The term was coined in 1990, but the phenomenon was first described after clinical ABO-incompatible (ABOi) renal transplantation in the 1980s and is recognized as a common outcome in this context today. Because of the absence, until recently of reliable animal models of allograft accommodation, it has been studied extensively by investigators in the xenotransplantation field. With recent advances in the ability to recognize and diagnose AMR in human organs, the growth of desensitization programmes for transplantation into sensitized recipients and the availability of therapies that have the potential to promote accommodation, it is timely to review the literature in this area, identifying lessons that may inform preclinical and clinical studies in the future. © copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2011        PMID: 22050724     DOI: 10.1111/j.1600-6143.2011.03821.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  9 in total

Review 1.  The role of complement in the early immune response to transplantation.

Authors:  Steven H Sacks; Wuding Zhou
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 2.  B cells in transplant tolerance and rejection: friends or foes?

Authors:  Robin Schmitz; Zachary W Fitch; Paul M Schroder; Ashley Y Choi; Annette M Jackson; Stuart J Knechtle; Jean Kwun
Journal:  Transpl Int       Date:  2020-01       Impact factor: 3.782

Review 3.  The role of complement in antibody mediated transplant rejection.

Authors:  Joshua M Thurman; Sarah E Panzer; Moglie Le Quintrec
Journal:  Mol Immunol       Date:  2019-06-10       Impact factor: 4.407

4.  Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-γ production by Th1 cells.

Authors:  Kin Yee Shiu; Laura McLaughlin; Irene Rebollo-Mesa; Jingyue Zhao; Hannah Burton; Harriet Douthwaite; Hannah Wilkinson; Vikki Semik; Philippa C Dodd; Paul Brookes; Robert I Lechler; Maria P Hernandez-Fuentes; Claudia Kemper; Anthony Dorling
Journal:  Kidney Int       Date:  2016-12-15       Impact factor: 10.612

5.  Desensitization protocol enabling pediatric crossmatch-positive renal transplantation: successful HLA-antibody-incompatible renal transplantation of two highly sensitized children.

Authors:  Anna M Adamusiak; Jelena Stojanovic; Olivia Shaw; Robert Vaughan; Neil J Sebire; Martin Drage; Nicos Kessaris; Stephen D Marks; Nizam Mamode
Journal:  Pediatr Nephrol       Date:  2016-09-01       Impact factor: 3.714

Review 6.  The Role of Complement in Organ Transplantation.

Authors:  Monica Grafals; Joshua M Thurman
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

Review 7.  Complement in ischaemia-reperfusion injury and transplantation.

Authors:  Mark C Howard; Christopher L Nauser; Conrad A Farrar; Steven H Sacks
Journal:  Semin Immunopathol       Date:  2021-11-10       Impact factor: 9.623

Review 8.  Computational Biology: Modeling Chronic Renal Allograft Injury.

Authors:  Mark D Stegall; Richard Borrows
Journal:  Front Immunol       Date:  2015-08-03       Impact factor: 7.561

9.  Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts.

Authors:  Kin Yee Shiu; Dominic Stringer; Laura McLaughlin; Olivia Shaw; Paul Brookes; Hannah Burton; Hannah Wilkinson; Harriet Douthwaite; Tjir-Li Tsui; Adam Mclean; Rachel Hilton; Sian Griffin; Colin Geddes; Simon Ball; Richard Baker; Candice Roufosse; Catherine Horsfield; Anthony Dorling
Journal:  Front Immunol       Date:  2020-02-05       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.